STAY CURRENT with FDA-Approved Immunotherapy Treatments from your Office or Home

SALT LAKE CITY LIVE VIRTUAL ACI
PROGRAM INFORMATION
Thursday, Feb. 18, 2021
3–8:30 p.m. MST

FREE for healthcare professionals, students, patients and patient advocates, the Society for Immunotherapy of Cancer (SITC) Advances in Cancer Immunotherapy™ (ACI) programs are presented by local authorities in tumor immunology and cancer immunotherapy. Earn your CME, CNE, CPE, and MOC credits while attending from the comfort of your own home or office!

ORGANIZERS:
Sumati Gupta, MD
Huntsman Cancer Institute
Megan Mullalley, PharmD, BCOP, BCPS
Intermountain Healthcare
Terence Rhodes, MD, PhD
Intermountain Healthcare

ACCREDITATION INFORMATION
AMA Credit Designation
This activity has been approved for AMA PRA Category 1 Credit(s)™.

Pharmacist Credit Designation
This activity is eligible for ACPE credit, see final CPE activity announcement for specific details.

Nursing Credit Designation
This activity is eligible for ANCC contact hours, see final CNE activity announcement for specific details.

SALT LAKE CITY LIVE VIRTUAL ACI
PROGRAM TAKEAWAYS
In addition to networking with fellow colleagues, highlights of the program include:

• Interactive, virtual setting to connect with local faculty and organizers
• Learning how to treat patients with FDA-approved immunotherapies
• A deep dive into identifying and managing irAEs
• COVID-19 considerations from the speakers’ direct experience
• Interpreting new clinical data supporting the use of checkpoint inhibitors, CAR T therapies, cytokines, oncolytic viruses and vaccines

For full accreditation information and to register for this event, please visit:
sitcancer.org/aci/saltlakecity

The 2020–2021 ACI series is jointly provided by the Postgraduate Institute for Medicine and the Society for Immunotherapy of Cancer in collaboration with the American Academy of Emergency Medicine, the Association of Community Cancer Centers and the Hematology/Oncology Pharmacy Association.

The 2020–2021 Advances in Cancer Immunotherapy™ educational series is supported, in part, by independent medical education grants from Amgen, AstraZeneca Pharmaceuticals LP, Bristol Myers Squibb, Exelixis, Inc. and Merck & Co., Inc.